Lista de obras -

Activation of the p53 pathway down-regulates the osteoprotegerin expression and release by vascular endothelial cells

artículo científico publicado en 2007

An imbalanced OPG/TRAIL ratio is associated to severe acute myocardial infarction

An increased osteoprotegerin serum release characterizes the early onset of diabetes mellitus and may contribute to endothelial cell dysfunction

artículo científico publicado en 2006

Antiangiogenic Activity of the MDM2 Antagonist Nutlin-3

artículo científico publicado en 2006

Association of tumor necrosis factor-related apoptosis-inducing ligand with total and cardiovascular mortality in older adults ⬇️

artículo científico publicado en 2010

Circulating levels of frizzled-related protein (FRZB) are increased in patients with early rheumatoid arthritis and decrease in response to disease-modifying antirheumatic drugs

artículo científico publicado en 2010

Conjunctival sac fluid contains elevated levels of soluble TRAIL: implications for the anti-tumoral surveillance of the anterior surface of the eye.

artículo científico publicado en 2009

Evidence for a proangiogenic activity of TNF-related apoptosis-inducing ligand

artículo científico publicado en 2004

Human bone marrow mesenchymal stem cells display anti-cancer activity in SCID mice bearing disseminated non-Hodgkin's lymphoma xenografts

artículo científico publicado en 2010

Human full-length osteoprotegerin induces the proliferation of rodent vascular smooth muscle cells both in vitro and in vivo

artículo científico publicado en 2009

In vivo anti-lymphoma activity of an agonistic human recombinant anti-TRAIL-R2 minibody

artículo científico publicado en 2010

MDM2 antagonist Nutlin-3 suppresses the proliferation and differentiation of human pre-osteoclasts through a p53-dependent pathway.

artículo científico publicado en 2007

Mesenchymal stem cells display hepato-protective activity in lymphoma bearing xenografts

artículo científico publicado en 2010

Metalloproteinase 2 cleaves in vitro recombinant TRAIL: potential implications for the decreased serum levels of TRAIL after acute myocardial infarction

artículo científico publicado en 2010

Nutlin-3 up-regulates the expression of Notch1 in both myeloid and lymphoid leukemic cells, as part of a negative feedback antiapoptotic mechanism

artículo científico publicado en 2009

Osteoprotegerin increases leukocyte adhesion to endothelial cells both in vitro and in vivo

artículo científico publicado en 2007

Osteoprotegerin induces morphological and functional alterations in mouse pancreatic islets

Potential prognostic significance of decreased serum levels of TRAIL after acute myocardial infarction

artículo científico publicado en 2009

Role of the RANKL/RANK system in the induction of interleukin-8 (IL-8) in B chronic lymphocytic leukemia (B-CLL) cells

artículo científico publicado en 2006

Selective induction of TP53I3/p53-inducible gene 3 (PIG3) in myeloid leukemic cells, but not in normal cells, by Nutlin-3.

artículo científico publicado en 2012

Systemic Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand Delivery Shows Antiatherosclerotic Activity in Apolipoprotein E–Null Diabetic Mice

scientific article published on 25 September 2006

TNF-alpha modulates the migratory response of mesenchymal stem cells to TRAIL.

artículo científico publicado en 2010

TRAIL counteracts the proadhesive activity of inflammatory cytokines in endothelial cells by down-modulating CCL8 and CXCL10 chemokine expression and release

artículo científico publicado en 2005

TRAIL inhibits osteoclastic differentiation by counteracting RANKL-dependent p27Kip1 accumulation in pre-osteoclast precursors

artículo científico publicado en 2008

The soluble terminal complement complex (SC5b-9) up-regulates osteoprotegerin expression and release by endothelial cells: implications in rheumatoid arthritis

artículo científico publicado en 2009

The tumour necrosis factor-related apoptosis-inducing ligand-osteoprotegerin system in limited systemic sclerosis: a new disease marker?

artículo científico publicado en 2010

Trail down-regulates the release of osteoprotegerin (OPG) by primary stromal cells

artículo científico publicado en 2011

Tumor necrosis factor-related apoptosis-inducing ligand promotes migration of human bone marrow multipotent stromal cells.

artículo científico publicado en 2008

Lista de obras de

Activation of the p53 pathway down-regulates the osteoprotegerin expression and release by vascular endothelial cells

An imbalanced OPG/TRAIL ratio is associated to severe acute myocardial infarction

An increased osteoprotegerin serum release characterizes the early onset of diabetes mellitus and may contribute to endothelial cell dysfunction

Antiangiogenic Activity of the MDM2 Antagonist Nutlin-3

Association of tumor necrosis factor-related apoptosis-inducing ligand with total and cardiovascular mortality in older adults ⬇️

Circulating levels of frizzled-related protein (FRZB) are increased in patients with early rheumatoid arthritis and decrease in response to disease-modifying antirheumatic drugs

Conjunctival sac fluid contains elevated levels of soluble TRAIL: implications for the anti-tumoral surveillance of the anterior surface of the eye.

Evidence for a proangiogenic activity of TNF-related apoptosis-inducing ligand

Human bone marrow mesenchymal stem cells display anti-cancer activity in SCID mice bearing disseminated non-Hodgkin's lymphoma xenografts

Human full-length osteoprotegerin induces the proliferation of rodent vascular smooth muscle cells both in vitro and in vivo

In vivo anti-lymphoma activity of an agonistic human recombinant anti-TRAIL-R2 minibody

MDM2 antagonist Nutlin-3 suppresses the proliferation and differentiation of human pre-osteoclasts through a p53-dependent pathway.

Mesenchymal stem cells display hepato-protective activity in lymphoma bearing xenografts

Metalloproteinase 2 cleaves in vitro recombinant TRAIL: potential implications for the decreased serum levels of TRAIL after acute myocardial infarction

Nutlin-3 up-regulates the expression of Notch1 in both myeloid and lymphoid leukemic cells, as part of a negative feedback antiapoptotic mechanism

Osteoprotegerin increases leukocyte adhesion to endothelial cells both in vitro and in vivo

Osteoprotegerin induces morphological and functional alterations in mouse pancreatic islets

Potential prognostic significance of decreased serum levels of TRAIL after acute myocardial infarction

Role of the RANKL/RANK system in the induction of interleukin-8 (IL-8) in B chronic lymphocytic leukemia (B-CLL) cells

Selective induction of TP53I3/p53-inducible gene 3 (PIG3) in myeloid leukemic cells, but not in normal cells, by Nutlin-3.

Systemic Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand Delivery Shows Antiatherosclerotic Activity in Apolipoprotein E–Null Diabetic Mice

TNF-alpha modulates the migratory response of mesenchymal stem cells to TRAIL.

TRAIL counteracts the proadhesive activity of inflammatory cytokines in endothelial cells by down-modulating CCL8 and CXCL10 chemokine expression and release

TRAIL inhibits osteoclastic differentiation by counteracting RANKL-dependent p27Kip1 accumulation in pre-osteoclast precursors

The soluble terminal complement complex (SC5b-9) up-regulates osteoprotegerin expression and release by endothelial cells: implications in rheumatoid arthritis

The tumour necrosis factor-related apoptosis-inducing ligand-osteoprotegerin system in limited systemic sclerosis: a new disease marker?

Trail down-regulates the release of osteoprotegerin (OPG) by primary stromal cells

Tumor necrosis factor-related apoptosis-inducing ligand promotes migration of human bone marrow multipotent stromal cells.